Does cosentyx weaken flu shot protection?
Cosentyx contains secukinumab, a monoclonal antibody that selectively targets IL-17A to reduce inflammation in conditions like psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By blocking IL-17A, it modulates immune responses, so it may affect how the body responds to vaccines.
What happens to flu shot effectiveness when taking Cosentyx?
Studies show that patients on secukinumab can still produce antibodies after influenza vaccination, but some research indicates the response may be lower than in patients not taking immunosuppressants. The manufacturers' data indicate that patients on Cosentyx should receive non-live vaccines like the flu shot before treatment begins whenever possible.
What guidelines do doctors follow when vaccinating patients on Cosentyx?
Clinical guidelines recommend completing non-live vaccines at least 2 weeks before starting Cosentyx. After treatment starts, vaccination is allowed but should be monitored closely for effectiveness and any adverse reactions. Doctors may check antibody levels or simply recommend the annual flu shot every year.
How does Cosentyx compare with other biologics in vaccine response?
Secukinumab and similar IL-17 inhibitors have a relatively mild impact on vaccine response compared to TNF inhibitors or JAK inhibitors. Some studies show TNF blockers like Humira may reduce vaccine antibody levels more strongly. Patients on Cosentyx may receive the flu shot even during treatment, but effectiveness can still be reduced.
When does Cosentyx patent expire?
Cosentyx is protected by patents until at least 2028. Biosimilars are unlikely to appear before then.